Pliant Therapeutics announces retirement of three directors and repricing of underwater stock options

PLIANT THERAPEUTICS, INC.

Directors David Pyott, Katharine Knobil, and Suzanne Bruhn will retire effective at the 2026 Annual Meeting; all departures are not due to any disagreements.
Board approved repricing of employee stock options (including executive officers) to $1.33 per share, effective April 17, 2026.
Repricing covers options granted on or before March 1, 2025 under the 2015, 2020, and 2022 equity plans; eligible participants must stay through a 12-18 month retention period.
Affected executive officers include CEO Bernard Coulie, CFO Keith Cummings, CHRO Lily Cheung, COO Minnie Kuo, CTO Delphine Imbert, and SVP Tim Machajewski.
Underwater options were repriced to retain talent without additional dilution or cash compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.